Synthesis of a poly(m-phenylene) by
Suzuki polycondensation (SPC) using an AB-type m-phenylene
monomer is reported (A and B refer to bromo and boron functional groups,
respectively). Despite the attempted high molecular weight products,
SPC under the conventional conditions using Pd[P(p-Tol)3]3 as catalyst gave rise to oligomeric
products only. They comprise cycles and several series of open-chain
poly(m-phenylene)s with various end group patterns.
These patterns were caused by side reactions such as ligand scrambling.
Buchwald’s SPhos ligand was therefore alternatively employed
for high turnover catalysis to accelerate SPC over such detrimental
side reactions. This modification indeed led to the formation of high
molecular weight products ∼40 kDa (DP ∼ 210), while
oligomeric cyclic products still remained prominent. Cycle formation
could, however, drastically be reduced by slow monomer addition. SPC
was also performed in the presence of an excess monofunctional compound,
R–A or R–B. The molecular weights of the products were
found to be sensitive to the presence of R–B but not so much
to R–A. This suggests a chain-growth-like mechanism as previously
reported by Yokozawa et al. The modified SPC protocol was also used
to demonstrate an efficient end-functionalization of the SPC products
at both A and B termini with distinct chemical moieties. This revealed
that the chain directionality expected from the AB monomer was largely
retained when Pd(dba)2 was used as palladium source for
the SPC catalyst but not as for Pd(OAc)2. This is presumably
due to involvement of the homocoupling between phenyl boronates leading
to reduction of Pd(II).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.